Ultragenyx Pharmaceutical Inc. announced preliminary unaudited total revenue for 2024 of $555 million to $560 million, surpassing previous guidance, particularly driven by Crysvita® sales of $405 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback